KRYS250117C155000
- 19.03
- 0.000.00%
Krystal Biotech Newsroom
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $196
Promising Clinical Data and Platform Potential Drive Buy Rating for Krystal Biotech
Krystal Biotech Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
Krystal Biotech Analyst Ratings
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
Optimistic Buy Rating for Krystal Biotech Driven by Promising Clinical Findings in Respiratory Platform
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $196
Krystal Biotech Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
Krystal Biotech Analyst Ratings
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
Positive Outlook for Krystal Biotech: Regulatory Advancements and Promising Pipeline Drive Buy Rating
Krystal Biotech Is Maintained at Neutral by Citigroup
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $206 to $221
Krystal Biotech's Strong Financial Performance and Strategic Advancements Drive Buy Rating
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $220